{
  "model": "gemini-flash-latest",
  "agentReasoning": "medium",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "workspacePath": "workspaces/gemini-flash-latest-tumor-vaccine-ici-run-1",
  "success": false,
  "schemaPass": false,
  "toolTracePass": true,
  "graderPass": false,
  "durationMs": 76432,
  "agentCostUsd": 0,
  "graderCostUsd": 0,
  "totalCostUsd": 0,
  "agentUsage": {
    "promptTokens": 52206,
    "cachedTokens": 37745,
    "responseTokens": 3274,
    "thinkingTokens": 6612,
    "totalTokens": 62092
  },
  "graderUsage": {
    "promptTokens": 0,
    "cachedTokens": 0,
    "responseTokens": 0,
    "thinkingTokens": 0,
    "totalTokens": 0
  },
  "totalUsage": {
    "promptTokens": 52206,
    "cachedTokens": 37745,
    "responseTokens": 3274,
    "thinkingTokens": 6612,
    "totalTokens": 62092
  },
  "modelVersions": [
    "gemini-flash-latest"
  ],
  "agentFinalText": "### Completion Checklist\nThe following required output files have been written:\n\n1.  `output/study_overview.json`\n2.  `output/quantitative_findings.json`\n3.  `output/claim_audit.json`\n4.  `output/public_summary.json`",
  "outputValidation": [
    {
      "outputFile": "output/study_overview.json",
      "schemaFile": "schemas/study_overview.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Does intratumoral delivery of an mRNA vaccine create an interferon-rich inflammatory state that improves tumor sensitivity to anti-PD-L1 therapy?\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-combo\",\n      \"label\": \"Mouse Efficacy Cohort (Combination)\",\n      \"sample_size_or_observations\": \"78\",\n      \"description\": \"Tumor-bearing mice receiving intratumoral mRNA vaccine and anti-PD-L1 combination therapy, pooled across repeat experiments.\"\n    },\n    {\n      \"id\": \"mouse-controls\",\n      \"label\": \"Mouse Control Cohort\",\n      \"sample_size_or_observations\": \"84\",\n      \"description\": \"Tumor-bearing mice pooled across matched controls including vaccine only, ICI only, and vehicle treatments.\"\n    },\n    {\n      \"id\": \"human-retrospective\",\n      \"label\": \"Human Retrospective Cohort\",\n      \"sample_size_or_observations\": \"130\",\n      \"description\": \"Metastatic patients receiving ICI treatment, retrospectively analyzed based on prior SARS-CoV-2 mRNA vaccination status (43 vaccinated, 87 unvaccinated).\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely.\",\n    \"Vaccination timing relative to ICI initiation varied across patients.\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\",\n    \"Mouse model effects may not map one-to-one to all human tumors.\"\n  ]\n}"
    },
    {
      "outputFile": "output/quantitative_findings.json",
      "schemaFile": "schemas/quantitative_findings.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\n        \"L28\"\n      ]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\n        \"L29\"\n      ]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\n        \"L30\"\n      ]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\n        \"L31\"\n      ]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\n        \"L32\"\n      ]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\n        \"L33\"\n      ]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n      \"evidence_line_ref\": \"L39\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\",\n      \"evidence_line_ref\": \"L38\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/claim_audit.json",
      "schemaFile": "schemas/claim_audit.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": false,
      "errors": [
        "Quote in C01 was not found verbatim in report: \"intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\""
      ],
      "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers a local innate sensing and strong type I interferon signaling response within the tumor microenvironment.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        },\n        {\n          \"quote\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\",\n          \"line_ref\": \"L39\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"mRNA vaccination significantly expands the repertoire of tumor-associated peptides presented on MHC-I, effectively increasing tumor visibility to T cells.\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination\",\n          \"line_ref\": \"L28\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        },\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\",\n          \"line_ref\": \"L44\"\n        }\n      ],\n      \"caveat\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models, suggesting the T cell response is insufficient without checkpoint blockade.\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Combining intratumoral mRNA vaccination with checkpoint blockade results in a synergistic anti-tumor effect, increasing T-cell infiltration and making the checkpoint axis more targetable.\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        },\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors, and ICI-only treatment had limited activity in low-immunogenic baseline settings.\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"In a retrospective analysis, prior SARS-CoV-2 mRNA vaccination is statistically associated with improved survival outcomes in metastatic cancer patients treated with Immune Checkpoint Inhibitors (ICI).\",\n      \"strength\": \"tentative\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\",\n          \"line_ref\": \"L15\"\n        },\n        {\n          \"quote\": \"The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.\",\n          \"line_ref\": \"L56\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing relative to ICI initiation varied across patients.\"\n    }\n  ]\n}"
    },
    {
      "outputFile": "output/public_summary.json",
      "schemaFile": "schemas/public_summary.schema.json",
      "exists": true,
      "jsonValid": true,
      "schemaValid": true,
      "groundingValid": true,
      "errors": [],
      "content": "{\n  \"headline\": \"mRNA Vaccines May Sensitize Tumors to Immunotherapy, New Study Suggests\",\n  \"plain_language_summary\": \"This study investigates a new strategy to improve cancer immunotherapy, specifically Immune Checkpoint Blockade (ICI), which often fails because tumors evade immune detection. In preclinical models, researchers found that injecting an mRNA vaccine (like those used for COVID-19) directly into a tumor creates a powerful local inflammatory state, characterized by high Type I Interferon signaling. This signal acts as an 'SOS,' significantly increasing the number of tumor antigens displayed on the cancer cell surface (MHC-I presentation), thus making the tumor more 'visible' to the immune system. The combination of this 'priming' vaccine and ICI therapy led to a synergistic anti-tumor effect, including increased cancer-fighting T-cell infiltration and better tumor control in mice. The hypothesis is supported by a retrospective analysis of metastatic patients, where those who had received a prior SARS-CoV-2 mRNA vaccine showed improved survival under ICI treatment (p=0.01). While promising, the authors caution that the human data is non-randomized and prospective trials are essential before any clinical changes are made.\",\n  \"what_is_new\": [\n    \"Intratumoral mRNA delivery strongly induces a type I interferon response in the tumor, which is identified as the crucial mechanism for sensitization.\",\n    \"This local inflammation significantly broadens the repertoire of tumor antigens presented on MHC-I, making the tumor more recognizable to T cells (62.3% vs 37.3% protein representation).\",\n    \"Mechanistic findings in mice (increased T-cell infiltration and tumor control) align with a statistical association of better survival in a retrospective cohort of ICI-treated human patients (p=0.01).\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human analysis is retrospective and non-randomized, meaning residual confounding is likely and the association does not prove causation.\",\n    \"The experimental models in mice used direct intratumoral injection, which is different from standard systemic vaccination, limiting direct clinical translation of the method.\",\n    \"The authors explicitly state that prospective randomized studies are required before any changes to current clinical protocol for ICI treatment are justified.\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"ICI (Immune Checkpoint Inhibitors)\",\n      \"definition\": \"A class of drugs that blocks inhibitory signals ('checkpoints') on immune cells, thereby releasing the 'brakes' and allowing the immune system to attack cancer cells.\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"Major Histocompatibility Complex Class I, a surface protein used by cells to display intracellular antigens (peptides) to cytotoxic T cells, crucial for tumor recognition.\"\n    },\n    {\n      \"term\": \"Type I Interferon Signaling\",\n      \"definition\": \"A powerful innate immune pathway triggered by viral components or nucleic acids, responsible for promoting inflammation and enhancing antigen processing.\"\n    },\n    {\n      \"term\": \"Retrospective Cohort\",\n      \"definition\": \"A study design that analyzes historical patient data and records, which is less rigorous than a prospective trial and subject to confounding factors.\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will a large-scale, randomized, prospective clinical trial confirm the survival benefit seen in the preliminary retrospective human cohort?\",\n    \"Is the observed sensitization a general effect of any mRNA/nanoparticle formulation, or is it dependent on the specific vaccine content or delivery method?\",\n    \"What is the optimal timing, dose, and route of administration for an mRNA vaccine to achieve therapeutic synergy with ICI in human patients?\"\n  ]\n}"
    }
  ],
  "toolTrace": {
    "pass": true,
    "totalCalls": 22,
    "failedCalls": 0,
    "toolsUsed": [
      "list_directory",
      "read_file",
      "write_file"
    ],
    "hasSuccessfulRead": true,
    "hasSuccessfulWrite": true,
    "pathPolicyViolations": [],
    "notes": [],
    "calls": [
      {
        "source": "llm",
        "step": 1,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 2,
        "toolName": "list_directory"
      },
      {
        "source": "llm",
        "step": 3,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 4,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 5,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 6,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 7,
        "toolName": "read_file"
      },
      {
        "source": "llm",
        "step": 8,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 9,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 10,
        "toolName": "write_file"
      },
      {
        "source": "llm",
        "step": 11,
        "toolName": "write_file"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "TASK.md",
        "timestamp": "2026-02-13T17:38:22.050Z"
      },
      {
        "source": "fs",
        "toolName": "list_directory",
        "action": "list",
        "path": "schemas",
        "timestamp": "2026-02-13T17:38:27.394Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "input/report.md",
        "timestamp": "2026-02-13T17:38:32.484Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/study_overview.schema.json",
        "timestamp": "2026-02-13T17:38:34.176Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/quantitative_findings.schema.json",
        "timestamp": "2026-02-13T17:38:35.537Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/claim_audit.schema.json",
        "timestamp": "2026-02-13T17:38:37.686Z"
      },
      {
        "source": "fs",
        "toolName": "read_file",
        "action": "read",
        "path": "schemas/public_summary.schema.json",
        "timestamp": "2026-02-13T17:38:40.295Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/study_overview.json",
        "timestamp": "2026-02-13T17:39:02.792Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/quantitative_findings.json",
        "timestamp": "2026-02-13T17:39:08.470Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/claim_audit.json",
        "timestamp": "2026-02-13T17:39:15.466Z"
      },
      {
        "source": "fs",
        "toolName": "write_file",
        "action": "write",
        "path": "output/public_summary.json",
        "timestamp": "2026-02-13T17:39:23.545Z"
      }
    ]
  },
  "grader": {
    "model": "chatgpt-gpt-5.2",
    "error": "LLM JSON call failed after 2 attempt(s)"
  }
}
